Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 9/2009 | NovoCure | Venture Round | - |
| 3/2017 | Grail | Series B | 0 |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 10/2010 | Intio | Series B | 8.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 1/2012 | Pronota | Series C | 4.8M |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | Neotract | Series B | 28.1M |
| 4/2006 | Pronota | Series A | 7.8M |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 11/2003 | CardioMEMS | Series B | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 7/2005 | Ilypsa | Series B | 36M |
| 7/2000 | Lumenos | Series B | 34M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 12/2007 | Mitralign | Series C | 0 |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 11/2010 | Syntaxin | Series C | 29M |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 7/2008 | CVRx | Series E | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 9/2002 | CellGate | Series D | 10M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 7/2013 | ReVision Optics | Series E | 55M |
| 11/2013 | Biocartis | Series E | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 6/2006 | Tengion | Series B | 50M |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 10/2007 | Tengion | Series C | 33M |
| 1/2015 | Willow | Series A | 15M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 8/2005 | Tengion | Series A | 39M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2013 | Nevro | Series C | 0 |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 11/2004 | Corthera | Series B | 15M |
| 8/2019 | CVRx | Series G | 93M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 11/2014 | La Lumiere | Series B | 20M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 1/2014 | PowerVision | Series D | 0 |
| 11/2011 | Biocartis | Series C | 95.8M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 2/2008 | InSound Medical | Series E | 11M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 10/2007 | Optherion | Series A | 37M |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 2/2009 | ImaCor | Series A | 0 |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2016 | Cala Health | Series B | 0 |
| 1/2011 | 23andMe | Series C | 9M |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 4/2010 | Biocartis | Series B | 40M |
| 9/2014 | Biocartis | Series F | 0 |
| 4/2002 | Replidyne | Series A | 13M |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 1/2012 | PowerVision | Series C | 12.5M |
| 6/2001 | NitroMed | Series E | 0 |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 9/2004 | Vascular Architects | Series E | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 7/2013 | CVRx | Series F | 0 |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 5/2007 | CVRx | Series D | 65M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 12/2012 | Biocartis | Series D | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 11/2009 | Celladon | Series C | 21.8M |
| 2/2012 | Celladon | Venture Round | 43M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
